Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Asset Writedowns and Impairment (2023 - 2025)

Candel Therapeutics recorded quarterly Asset Writedowns and Impairment of $7000.0 in Q4 2025, up 600.0% quarter-over-quarter from $1000.0 in Q3 2025, and down 82.93% year-over-year from $41000.0 in Q4 2024.

Candel Therapeutics' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $7000.0 for Q4 2025.

  • In Q4 2025, Asset Writedowns and Impairment fell 82.93% year-over-year to $7000.0; the TTM figure through Dec 2025 stood at $277000.0 (changed N/A YoY), while the FY2025 annual figure was $90000.0, up 119.51% from the prior year.
  • Asset Writedowns and Impairment came in at $7000.0 for Q4 2025 at Candel Therapeutics, up from $1000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $228000.0 in Q4 2023 to a low of $1000.0 in Q3 2025.
  • A 3-year average of $69250.0 and a median of $24000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
  • Across the five-year window, Asset Writedowns and Impairment tumbled 82.02% in 2024 and sank 82.93% in 2025, its largest moves.
  • Candel Therapeutics' Asset Writedowns and Impairment stood at $228000.0 in 2023, then sank by 82.02% to $41000.0 in 2024, then tumbled by 82.93% to $7000.0 in 2025.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $7000.0, $1000.0, and $41000.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Candel Therapeutics 449.62 Mn 449.62 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 7,000.00
Dec 31, 2025 7,000.00
Sep 30, 2025 1,000.00
Sep 30, 2025 1,000.00
Dec 31, 2024 41,000.00
Dec 31, 2024 41,000.00
Dec 31, 2023 228,000.00
Dec 31, 2023 228,000.00